Celltrion, Incorporation operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Celltrion, Incorporation with three other
companies in this sector in South Korea:
Samsung Biologics Co Ltd
sales of 464.63 billion Korean Won [US$412.59 million]
of which 100%
was Biological Medicine Production),
Green Cross Corporation
(1.29 trillion Korean Won [US$1.14 billion]
of which 85%
was Greencross), and
Celltrion HealthCare Co Ltd
(920.92 billion Korean Won [US$817.78 million]
Celltrion, Incorporation reported sales of 949.08 billion Korean Won (US$842.78 million)
December of 2017.
increase of 41.5%
versus 2016, when the company's sales were 670.58 billion Korean Won.
This was the fourth straight year of sales growth at Celltrion, Incorporation.
Sales of Bio Business Division saw an increase
43.5% in 2017, from
577.57 billion Korean Won to 828.92 billion Korean Won.
Not all segments of Celltrion, Incorporation experienced an increase in sales in 2017:
sales of Other Segment fell 0.7% to 8.84 billion Korean Won.
(However, this segment's sales were only a very small portion of the company's overall sales).